Supernus shareholders are investigating a potential sale of the company to Indivior.
3 reports, 2 independent
Updated Mon 00:00
No new developments lately
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Supernus shareholders are investigating a potential sale of the company to Indivior.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.The merger aims to achieve $125M in cost synergies.1 source
Indivior is acquiring Supernus Pharmaceuticals, leading to its replacement in the S&P SmallCap 600.1 source
Supernus shareholders are investigating a potential sale to Indivior.1 source
Keep exploring
The entities involved
-
Indivior
specialty pharmaceuticals business headquartered in Richmond, Virginia
Nothing else this week.